Tarsus Pharmaceuticals (TARS) EBITDA Margin Growth (3y) (2024 - 2026)

Tarsus Pharmaceuticals (TARS) EBITDA Margin Growth (3y) (2024 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 9,942.00
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 530.00
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -1,211.00
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -623.00
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Tarsus Pharmaceuticals 2.52 Bn 2.41 Bn 152.66 Mn 99,430.00

Historic Data

Download Data
DateValue
Mar 31, 2026 99,430.00
Dec 31, 2025 14,535.00
Jun 30, 2025 1,259.00
Mar 31, 2025 358,816.00
Dec 31, 2024 423,778.00
Sep 30, 2024 121,424.00
Jun 30, 2024 -11,467.00
Mar 31, 2024 -16,851.00